Literature DB >> 28479841

Hepatitis C in a New Era: A Review of Current Therapies.

Troy Kish, Andrew Aziz, Monica Sorio.   

Abstract

The authors summarize newly available HCV treatment regimens, their indications, studies supporting their efficacy and safety, and special considerations for each regimen, such as patient comorbidities.

Entities:  

Year:  2017        PMID： 28479841      PMCID： PMC5398625     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  55 in total

1.  Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.

Authors:  Jordan J Feld; Christophe Moreno; Roger Trinh; Edward Tam; Stefan Bourgeois; Yves Horsmans; Magdy Elkhashab; David E Bernstein; Ziad Younes; Robert W Reindollar; Lois Larsen; Bo Fu; Kevin Howieson; Akshanth R Polepally; Andreas Pangerl; Nancy S Shulman; Fred Poordad
Journal:  J Hepatol       Date:  2015-10-22       Impact factor: 25.083

2.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

3.  Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Authors:  Marc Bourlière; Jean-Pierre Bronowicki; Victor de Ledinghen; Christophe Hézode; Fabien Zoulim; Philippe Mathurin; Albert Tran; Dominique G Larrey; Vlad Ratziu; Laurent Alric; Robert H Hyland; Deyuan Jiang; Brian Doehle; Phillip S Pang; William T Symonds; G Mani Subramanian; John G McHutchison; Patrick Marcellin; François Habersetzer; Dominique Guyader; Jean-Didier Grangé; Véronique Loustaud-Ratti; Lawrence Serfaty; Sophie Metivier; Vincent Leroy; Armand Abergel; Stanislas Pol
Journal:  Lancet Infect Dis       Date:  2015-03-13       Impact factor: 25.071

4.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

6.  Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

Authors:  Maria Buti; Stuart C Gordon; Eli Zuckerman; Eric Lawitz; Jose L Calleja; Harald Hofer; Christopher Gilbert; John Palcza; Anita Y M Howe; Mark J DiNubile; Michael N Robertson; Janice Wahl; Eliav Barr; Xavier Forns
Journal:  Clin Infect Dis       Date:  2015-09-14       Impact factor: 20.999

Review 7.  Understanding Cost and Value in Hepatitis C Therapy.

Authors:  Benjamin P Linas
Journal:  Top Antivir Med       Date:  2016 Jul/Aug

8.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

9.  Testing for HCV infection: an update of guidance for clinicians and laboratorians.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-05-10       Impact factor: 17.586

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
View more
  16 in total

1.  Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis.

Authors:  Arun Jose; Shimul A Shah; Nadeem Anwar; Courtney R Jones; Francis X McCormack; Kenneth E Sherman; Jean M Elwing
Journal:  Respir Med       Date:  2021-11-11       Impact factor: 3.415

Review 2.  Drug combination therapy for emerging viral diseases.

Authors:  Zeenat A Shyr; Yu-Shan Cheng; Donald C Lo; Wei Zheng
Journal:  Drug Discov Today       Date:  2021-05-21       Impact factor: 7.851

3.  Viral replicons as valuable tools for drug discovery.

Authors:  Holger Hannemann
Journal:  Drug Discov Today       Date:  2020-04-06       Impact factor: 7.851

4.  Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation.

Authors:  Xianting Ding; Peter O Krutzik; Amir Ali Ghaffari; Yixiu Zhaozhi; Daniel Miranda; Genhong Cheng; Chih-Ming Ho; Garry P Nolan; David Jesse Sanchez
Journal:  Antiviral Res       Date:  2019-09-09       Impact factor: 5.970

5.  Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections.

Authors:  Tania M Welzel; Min Yang; Gautam Sajeev; Yaozhu J Chen; Brett Pinsky; Yanjun Bao; Eric Q Wu; Douglas Dieterich
Journal:  Adv Ther       Date:  2019-06-25       Impact factor: 3.845

6.  Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.

Authors:  Cody Orr; Wenjie Xu; Henry Masur; Shyam Kottilil; Eric G Meissner
Journal:  BMC Infect Dis       Date:  2020-12-04       Impact factor: 3.090

7.  Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy.

Authors:  Nadia A Nabulsi; Michelle T Martin; Lisa K Sharp; David E Koren; Robyn Teply; Autumn Zuckerman; Todd A Lee
Journal:  Front Pharmacol       Date:  2020-11-13       Impact factor: 5.810

8.  Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.

Authors:  Rodolfo Sacco; Vincenzo Messina; Umberto Vespasiani Gentilucci; Luigi Elio Adinolfi; Antonio Ascione; Giorgio Barbarini; Angelo Barlattani; Giuseppe Cariti; Raffaele Cozzolongo; Basilio Fimiani; Ruggiero Francavilla; Caterina Furlan; Giovanni Garrucciu; Vincenzo Iovinella; Luca Rinaldi; Massimo Marignani; Paola Begini; Valeria Pace Palitti; Adriano M Pellicelli; Gaetano Scifo; Antonio Facciorusso; Luca Giacomelli; Aashni Shah; Gaetano Bertino; Serena Perazzo; Giampaolo Bresci; Antonio Izzi
Journal:  Drugs Context       Date:  2020-12-15

9.  Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly.

Authors:  Adam Rolt; Daniel C Talley; Seung Bum Park; Zongyi Hu; Andrés Dulcey; Christopher Ma; Parker Irvin; Madeleine Leek; Amy Q Wang; Andrew V Stachulski; Xin Xu; Noel Southall; Marc Ferrer; T Jake Liang; Juan J Marugan
Journal:  J Med Chem       Date:  2021-06-29       Impact factor: 7.446

10.  Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis.

Authors:  Saptaparni Ghosh; Minghua L Chen; Janice Weinberg; Tsion Fikre; Naomi Y Ko
Journal:  Oncologist       Date:  2020-06-26       Impact factor: 5.837
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.